Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell ... - MarketWatch (press release)

Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell ...
MarketWatch (press release)
In preclinical studies, Nexavar has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases include Raf kinase, ...

and more »

continue reading

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of ... - MarketWatch (press release)

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of ...
MarketWatch (press release)
A new drug application (NDA) for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies is currently being reviewed by the US FDA, and the anticipated date for completion of ...

and more »

continue reading